Anzeige
Mehr »
Donnerstag, 07.08.2025 - Börsentäglich über 12.000 News
Große CEO-Enthüllung: Analysten sehen +56% Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QB4J | ISIN: US82686Q1013 | Ticker-Symbol: XRP2
Tradegate
04.08.25 | 21:41
5,150 Euro
+11,47 % +0,530
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
SILENCE THERAPEUTICS PLC ADR Chart 1 Jahr
5-Tage-Chart
SILENCE THERAPEUTICS PLC ADR 5-Tage-Chart
RealtimeGeldBriefZeit
4,5604,66022:52
4,4804,74022:00

Aktuelle News zur SILENCE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:05Silence Therapeutics plc - 10-Q, Quarterly Report1
13:36Silence Therapeutics plc: Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights157Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV SANRECO Phase 2 Study On-Track for Complete Enrollment by Year-End 2025 Silence...
► Artikel lesen
13:35Silence Therapeutics plc - 8-K, Current Report3
27.06.Silence Therapeutics plc - 8-K, Current Report4
SILENCE THERAPEUTICS Aktie jetzt für 0€ handeln
13.06.H.C. Wainwright reiterates buy rating on Silence Therapeutics stock5
12.06.Silence Therapeutics plc: Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera455Updated Phase 1 Data Presented at EHA 2025 Annual Meeting Reinforce Safety Profile, Efficacy Data and Dosing Convenience of Divesiran Company Also Announces SANRECO Phase 2 Study Has Exceeded...
► Artikel lesen
08.05.Silence Therapeutics plc GAAP EPS of -C$0.204
08.05.Silence Therapeutics plc - 10-Q, Quarterly Report3
08.05.Silence Therapeutics plc: Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights1.098Company further extends cash guidance into 2028 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global clinical-stage company developing novel siRNA (short interfering RNA)...
► Artikel lesen
06.05.Silence Therapeutics plc - 8-K, Current Report3
06.05.Silence Therapeutics plc: Silence Therapeutics Welcomes Tim McInerney to Board of Directors422Mr. McInerney brings over 30 years of industry experience spanning senior executive, finance and capital advisory roles in the pharmaceutical and biotechnology sectors Silence Therapeutics plc...
► Artikel lesen
30.04.Silence Therapeutics plc - 10-K/A, Annual Report2
24.04.Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying4
07.03.H.C. Wainwright maintains $75 target on Silence Therapeutics stock3
05.03.Silence Therapeutics plc: Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference336Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present...
► Artikel lesen
05.03.Morgan Stanley cuts Silence Therapeutics stock target to $454
04.03.Deep Dive Into Silence Therapeutics Stock: Analyst Perspectives (7 Ratings)2
27.02.Jefferies cuts Silence Therapeutics price target to $3016
27.02.Silence Therapeutics plc - S-8, Securities to be offered to employees in employee benefit plans2
27.02.Silence Therapeutics plc - 10-K, Annual Report-
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2